Related Experiment Video

Updated: Aug 15, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance

Mitch Dowsett1, Robert I Nicholson, Richard J Pietras

  • 1Academic Department of Biochemistry, Royal Marsden Hospital, London, UK. dowsett@icr.ac.uk

Breast Cancer Research and Treatment
|October 26, 2005
PubMed

Insights

Fulvestrant effectively treats advanced breast cancer in postmenopausal women by degrading estrogen receptors. Combining it with growth factor inhibitors may offer a new strategy against endocrine resistance.

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Endocrine resistance is a major challenge in breast cancer treatment.
  • Interactions between growth factor and estrogen receptor (ER) signaling pathways are implicated in endocrine resistance.
  • Targeting these pathways offers a strategy for ER-positive, endocrine-resistant tumors.

Purpose of the Study:

  • To evaluate fulvestrant, a novel ER antagonist, for treating endocrine-resistant breast cancer.
  • To explore the potential of combining fulvestrant with growth factor targeted agents.

Main Methods:

  • Fulvestrant was investigated for its ability to bind, block, and degrade the ER, inhibiting estrogen-sensitive gene transcription.
  • Preclinical studies assessed fulvestrant's efficacy in tamoxifen-resistant and sensitive breast cancer cell lines.
  • Clinical studies evaluated fulvestrant in postmenopausal women with advanced breast cancer.
  • Preclinical studies examined combinations of fulvestrant with EGFR inhibitors (gefitinib) and anti-HER2 antibodies (trastuzumab).

Main Results:

  • Fulvestrant demonstrated efficacy in postmenopausal women with advanced breast cancer after prior endocrine therapy.
  • Preclinical data showed fulvestrant inhibited both tamoxifen-resistant and sensitive breast cancer cell lines.
  • Combinations of fulvestrant with growth factor targeted agents showed potential for enhanced anti-tumor activity.

Conclusions:

  • Fulvestrant is an effective treatment for advanced breast cancer in postmenopausal women progressing on prior endocrine therapy.
  • Combining fulvestrant with growth factor targeted agents may represent a novel therapeutic strategy for hormone receptor-positive advanced breast cancer.
  • Ongoing clinical trials are investigating the efficacy of combination therapies to overcome endocrine resistance.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...